Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2008

View Archived Issues

Nasal hepatitis B vaccine shows promise in animal studies

Elixir Pharmaceuticals presents structure, preclinical pharmacology of EX-1314

Pardoprunox meets safety and efficacy endpoints in phase II Parkinson's disease studies

Souvenaid improves memory in mild Alzheimer's disease patients

COX-2 inhibitor NS-398 modulates effects of nitroglycerin-induced migraine in rats

Novel antiinflammatory TRPV1 antagonists identified at Johnson & Johnson

AstraZeneca reports compounds inhibiting Helicobacter pylori glutamate racemase

Novel treatment options for metabolic disorders claimed in recent patents

Recent patents describe new agents for cardiovascular disorders

Novel treatment for HCV infection reported in recent Bristol-Myers Squibb patent

Asterand enters license agreement with Allergan for prostaglandin receptor agonists

FDA grants IND for Davanat to treat breast cancer

FDA issues complete response to BioDelivery's Onsolis NDA

Phase I Oralair Grasses study shows positive results in allergen challenge

Phase II Juvista trial in scar revision meets primary endpoint

Valeant and GlaxoSmithKline enter worldwide collaboration for retigabine

Cyclacel reports IDRC conclusions for seliciclib phase IIb APPRAISE trial

Genetech to commence phase II GDC-0449 ovarian cancer trial

Novartis terminates development of Aurograb

Allon presents phase II MCI-CABG results

Takeda and Affymax focus Hematide development on kidney-related anemia

FDA grants orphan drug status to NGR-hTNF in malignant pleural mesothelioma

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.